导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.92% | 4203/4773 |
| 近一周 | -2.94% | 4419/5465 |
| 近一月 | -4.41% | 3227/5421 |
| 近一季 | 0.38% | 927/5231 |
| 近半年 | -15.22% | 4059/4920 |
| 近一年 | -22.37% | 3993/4394 |
| 近两年 | -4.68% | 2929/2954 |
| 近三年 | -27.92% | 2193/2253 |
| 成立以来 | 59.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.11% 4033/4961 |
-15.02% 4633/5312 |
- - |
- - |
| 2025 | -2.88% 3345/4813 |
1.88% 1528/3635 |
-5.10% 3535/4076 |
5.68% 3571/4524 |
-4.94% 3499/4813 |
| 2024 | -3.17% 2210/3463 |
0.99% 913/2808 |
-8.39% 2227/3014 |
14.89% 1886/3129 |
-8.91% 2889/3463 |
| 2023 | -16.61% 1690/2656 |
1.86% 1496/2280 |
-11.85% 2168/2385 |
-0.71% 437/2515 |
-6.46% 1786/2655 |
| 2022 | -11.01% 226/2207 |
-17.61% 1227/1919 |
23.35% 15/2016 |
-11.85% 598/2113 |
-0.67% 1636/2208 |
| 2021 | 1.88% 650/1822 |
-2.98% 737/1255 |
7.99% 651/1330 |
-6.85% 1003/1466 |
4.39% 335/1822 |
| 2020 | 69.06% 79/1250 |
-2.37% 260/1028 |
23.75% 187/1067 |
15.67% 202/1164 |
20.97% 59/1184 |
| 2019 | - - |
- - |
6.01% 12/788 |
5.15% 162/850 |
4.38% 804/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 前海开源MSCI中国A股消费A VS. 长安沪深300非周期A(740101) |